Systemic Vasculitis in Children
1. Ayush Singh
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Systemic vasculitis in children comprises a heterogeneous group of rare inflammatory disorders characterized by blood vessel wall inflammation that can lead to ischemia, organ dysfunction, and significant long-term morbidity if not recognized and treated promptly. Unlike adult forms, pediatric vasculitides show distinct epidemiological patterns, with immunoglobulin A vasculitis (IgAV, formerly Henoch-Schönlein purpura) and Kawasaki disease (KD) predominating, while antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), polyarteritis nodosa (PAN), and Takayasu arteritis (TA) remain uncommon. Classification relies primarily on the predominant size of affected vessels, guided by the 2012 Chapel Hill Consensus Conference nomenclature and pediatric-specific Ankara 2008 criteria endorsed by EULAR/PRINTO/PReS. Clinical presentations range from self-limited cutaneous and joint involvement to life-threatening multi-organ disease, including coronary artery aneurysms in KD, rapidly progressive glomerulonephritis in AAV, and ischemic complications in medium- and large-vessel disease. Diagnosis requires careful exclusion of mimics, integration of clinical findings, laboratory markers (including ANCA), imaging, and selective biopsy. Treatment has evolved from broad immunosuppression toward more targeted approaches, with intravenous immunoglobulin (IVIG) remaining foundational for KD, glucocorticoids and supportive care for most IgAV cases, and induction regimens combining glucocorticoids with cyclophosphamide or rituximab for severe AAV and PAN. Outcomes have improved with earlier recognition and collaborative research, yet challenges persist in refractory disease, long-term sequelae, and the need for pediatric-specific trial data. This review synthesizes current understanding of epidemiology, pathogenesis, clinical features, diagnosis, and management, emphasizing the importance of multidisciplinary care tailored to the developing child.
Introduction
Vasculitis refers to inflammation of blood vessel walls that disrupts vascular integrity and blood flow, producing tissue ischemia and organ damage of varying severity. In children the condition is uncommon overall yet clinically important because of its potential for rapid progression and lasting effects on growth, organ function, and quality of life. Primary systemic vasculitides arise without an identifiable underlying disease, whereas secondary forms accompany infection, drugs, malignancy, or other rheumatic conditions. Pediatric disease differs from adult counterparts in several respects: certain entities such as IgAV and KD occur almost exclusively in childhood, female predominance is more pronounced in some AAV subtypes, and long-term considerations must account for ongoing growth and development.
Incidence estimates for primary vasculitis in children under 17 years range from approximately 12 to 53 cases per 100 000, with marked geographic and ethnic variation. IgAV is the most frequent worldwide, with reported annual rates near 20–30 per 100 000 children and peaks between ages 4 and 6 years; higher figures have been noted in East Asian populations. KD shows striking geographic clustering, reaching incidences of 200–300 per 100 000 children under 5 years in Japan and Korea, while remaining lower (around 20 per 100 000) in Western countries. Medium- and large-vessel diseases and AAV are rarer, with annual incidences typically below 5–6 per million for AAV and 1–3 per million for TA and childhood PAN. Environmental factors, particularly preceding infections, appear to contribute to disease onset; seasonal patterns and reductions in KD incidence observed during periods of reduced pathogen circulation support this association.
The Chapel Hill Consensus Conference of 2012 refined nomenclature according to vessel size and provided disease definitions that remain widely used. Pediatric-specific classification criteria developed through the Ankara 2008 consensus and endorsed by EULAR, PRINTO, and PReS improved sensitivity for IgAV, childhood PAN, granulomatosis with polyangiitis (GPA), and TA. These frameworks classify disease as predominantly large-vessel (TA), medium-vessel (KD, PAN), or small-vessel (IgAV, AAV subtypes). Small-vessel disease is further subdivided into granulomatous and non-granulomatous forms. Recent adult ACR/EULAR criteria for AAV subtypes have begun to be evaluated in pediatric cohorts, with generally good performance but occasional discrepancies that underscore the need for continued pediatric validation.
Pathogenesis remains incompletely understood and likely involves an interplay of genetic predisposition, immune dysregulation, and environmental triggers. In IgAV, aberrant glycosylation of IgA1 leads to immune-complex deposition in small vessels of skin, gut, joints, and kidneys. KD is thought to represent an abnormal immune response to an unidentified infectious trigger in genetically susceptible hosts, producing systemic inflammation with particular tropism for coronary arteries. AAV is characterized by ANCA directed against proteinase-3 or myeloperoxidase that activate neutrophils and promote vessel-wall injury. Genetic associations, including HLA alleles and variants in immune-regulatory genes, are increasingly recognized, and monogenic forms of vasculitis have expanded the differential diagnosis in early-onset or familial cases.
Clinical suspicion should arise whenever a child presents with unexplained systemic inflammation, multi-organ involvement, or characteristic cutaneous findings such as palpable purpura or livedo. Constitutional symptoms (fever, fatigue, weight loss), musculoskeletal complaints, hypertension, neurologic deficits, pulmonary infiltrates or hemorrhage, and renal abnormalities all warrant consideration of vasculitis. Differential diagnosis is broad and includes infection, malignancy, other connective-tissue diseases, and non-inflammatory vasculopathies. Prompt recognition is essential because delayed treatment increases the risk of irreversible organ damage, particularly coronary aneurysms in KD and renal scarring in IgAV or AAV.
This article adopts an IMRAD structure to organize current knowledge. The Methods section outlines the approach to synthesizing the literature. Results summarize key epidemiologic, clinical, diagnostic, and therapeutic data for the major pediatric systemic vasculitides. Discussion interprets these findings, highlights remaining gaps, and considers implications for clinical practice and research.
Methods
This narrative review was constructed from recent peer-reviewed literature on childhood systemic vasculitis, with emphasis on publications from 2017 onward and priority given to systematic reviews, international classification criteria, consensus recommendations, and large cohort studies. Sources included PubMed/MEDLINE, major rheumatology and pediatric journals, and open-access repositories. Search terms encompassed combinations of “pediatric vasculitis,” “childhood vasculitis,” “IgA vasculitis,” “Kawasaki disease,” “ANCA-associated vasculitis,” “polyarteritis nodosa,” “Takayasu arteritis,” together with modifiers for epidemiology, pathogenesis, classification, diagnosis, treatment, and outcome. Particular attention was paid to the 2012 Chapel Hill nomenclature, Ankara 2008 pediatric classification criteria, American Heart Association guidelines for KD, SHARE and other European recommendations, and emerging data on biologic therapies and genetic insights. Preference was given to studies reporting pediatric-specific data rather than extrapolated adult findings. Where quantitative estimates varied across populations, ranges and sources of heterogeneity are noted. The synthesis aims for clinical relevance while remaining faithful to the evidence base; it does not constitute a formal systematic review with meta-analysis.
Results
Epidemiologic data confirm that IgAV and KD account for the large majority of childhood systemic vasculitis cases. IgAV incidence is highest in children under 10 years, with a modest male predominance, and is frequently preceded by upper-respiratory infection. Renal involvement occurs in 20–50 percent of patients and is the principal determinant of long-term prognosis; progression to chronic kidney disease remains uncommon but is more likely with nephrotic-range proteinuria, reduced glomerular filtration rate, or persistent abnormalities. Gastrointestinal complications, including intussusception and hemorrhage, affect a substantial minority and may require surgical intervention.
KD presents almost exclusively in children under 5 years and is defined by prolonged fever plus a constellation of mucocutaneous and extremity changes, or by incomplete criteria plus coronary-artery abnormalities on echocardiography. Coronary aneurysms develop in approximately 25 percent of untreated patients and remain the leading cause of acquired heart disease in children in developed countries. Prompt administration of IVIG reduces this risk substantially. Incomplete or atypical presentations are more common in infants and older children and carry higher risk of coronary complications if treatment is delayed.
AAV is rare, with annual incidence estimates ranging from 0.4 to roughly 6 per million children. GPA is the most frequent subtype, followed by microscopic polyangiitis (MPA); eosinophilic granulomatosis with polyangiitis (EGPA) is exceedingly uncommon. Pediatric AAV shows a female predominance and median age at diagnosis in the early second decade. Upper-airway disease, pulmonary nodules or hemorrhage, and pauci-immune glomerulonephritis are characteristic of GPA; MPA more often presents with renal-limited or pulmonary-renal disease. ANCA testing (PR3-ANCA/cANCA or MPO-ANCA/pANCA) supports diagnosis but is not invariably positive. Delayed recognition remains a problem, with median symptom duration before diagnosis sometimes exceeding one to two years in older series.
Childhood PAN is a necrotizing vasculitis of medium-sized arteries that may present with systemic features (fever, weight loss, myalgia, livedo, hypertension, neuropathy, or organ infarction) or as a cutaneous-limited form. Angiographic demonstration of aneurysms, stenoses, or occlusions, or histologic confirmation of necrotizing vasculitis, is required for classification. Hepatitis B association is less common in contemporary pediatric series than historically. TA, a large-vessel granulomatous vasculitis, predominantly affects the aorta and its major branches. Presentation is often insidious, with constitutional symptoms, hypertension, pulse deficits, bruits, and claudication. Imaging (magnetic resonance angiography, computed tomography angiography, or conventional angiography) is essential for diagnosis and monitoring. Pediatric TA may show higher rates of active inflammation and need for aggressive immunosuppression compared with adult disease.
Diagnostic evaluation begins with thorough history and examination, followed by laboratory assessment of acute-phase reactants, complete blood count, renal and hepatic function, urinalysis, and disease-specific serologies (ANCA, antinuclear antibodies when indicated). Skin or organ biopsy is valuable when the diagnosis is uncertain or when histologic confirmation will alter management; immunofluorescence demonstrating IgA-dominant deposits supports IgAV. Imaging is central for medium- and large-vessel disease: echocardiography for KD, angiography or cross-sectional vascular imaging for PAN and TA. Disease activity instruments such as the Pediatric Vasculitis Activity Score (PVAS) facilitate standardized assessment in clinical care and research.
Treatment strategies are disease- and severity-specific. For uncomplicated IgAV, supportive care and analgesia usually suffice; glucocorticoids are reserved for significant abdominal pain, orchitis, or severe cutaneous disease and are not recommended prophylactically to prevent nephritis. Moderate to severe IgAV nephritis may require glucocorticoids, and more intensive immunosuppression (mycophenolate, cyclophosphamide, or rituximab) is considered for crescentic or refractory disease according to recent guidelines. KD treatment centers on timely IVIG (2 g/kg as a single infusion) plus aspirin; refractory cases may receive additional IVIG, corticosteroids, infliximab, or other agents. For severe AAV and systemic PAN, induction therapy typically combines high-dose glucocorticoids with cyclophosphamide or rituximab, followed by maintenance with azathioprine, mycophenolate, or rituximab. Biologic agents targeting TNF-α or IL-6 have shown utility in refractory TA and selected other vasculitides. Supportive measures, blood-pressure control, infection prophylaxis, and attention to growth, bone health, and psychosocial needs are integral throughout.
Outcomes have improved substantially. Five-year survival exceeds 99 percent for treated KD and is generally favorable for IgAV, although a subset of patients develop chronic kidney disease decades later. Survival in childhood AAV and PAN now approaches 80–90 percent or higher with modern regimens, yet relapse rates remain significant and cumulative organ damage is common. Long-term cardiovascular sequelae of KD and TA necessitate lifelong surveillance.
Discussion
The landscape of pediatric systemic vasculitis has advanced through collaborative registries, refined classification criteria, and gradual accumulation of treatment experience, yet substantial challenges remain. The predominance of IgAV and KD in childhood means that most pediatricians will encounter these entities, while rarer forms demand specialized multidisciplinary expertise. Early recognition continues to be the single most important modifiable factor influencing prognosis, particularly for KD, where treatment within the first ten days of fever markedly reduces coronary complications, and for AAV, where delayed diagnosis risks irreversible renal or pulmonary damage.
Classification systems have matured, yet perfect concordance between adult-derived and pediatric criteria is lacking. Application of the 2022 ACR/EULAR AAV criteria to pediatric cohorts reclassifies a non-negligible fraction of patients relative to earlier algorithms, highlighting the need for age-specific validation. Pathogenetic insights—IgA1 glycosylation abnormalities, ANCA-mediated neutrophil activation, and possible infectious triggers—offer rational targets for therapy, but translation into pediatric practice is constrained by the rarity of disease and consequent scarcity of randomized trials. Most treatment recommendations therefore rest on observational data, expert consensus, and extrapolation from adult studies, with appropriate caution regarding dosing, toxicity, and developmental effects.
Therapeutic progress is evident. IVIG transformed the natural history of KD. Rituximab has become an established alternative or adjunct to cyclophosphamide in AAV, reducing cumulative cyclophosphamide exposure and associated infertility and malignancy risks. Biologics have expanded options for refractory TA and selected other vasculitides. Nevertheless, glucocorticoid toxicity remains a major concern in growing children, and steroid-sparing strategies deserve continued emphasis. Supportive and preventive care—infection prophylaxis, vaccination timing, cardiovascular risk modification, and transition to adult services—are as important as immunosuppressive regimens.
Future directions include deeper genetic and multi-omic characterization to enable precision medicine, development of reliable biomarkers for disease activity and damage, and international collaborative trials that can enroll sufficient pediatric patients. Artificial-intelligence approaches to imaging and risk prediction are beginning to appear and may assist earlier diagnosis. Attention to patient- and family-reported outcomes, long-term quality of life, and the psychosocial burden of chronic illness will further humanize care.
In clinical practice, a high index of suspicion, systematic evaluation, and readiness to initiate treatment while diagnostic work-up proceeds remain essential. Multidisciplinary teams that include pediatric rheumatologists, nephrologists, cardiologists, radiologists, and pathologists optimize outcomes. Families benefit from clear communication about prognosis, the rationale for treatment, and the importance of adherence and surveillance. Although systemic vasculitis in children is uncommon, its impact can be profound; informed, timely, and compassionate care can substantially alter the trajectory for affected children and their families.
References
Ahn JG. Overview of childhood vasculitis. J Rheum Dis. 2024;31(3):135-142.
Bayındır Y, Başaran Ö, Bilginer Y, Özen S. Vasculitis in Children. Turk Arch Pediatr. 2024;59(6):517-526.
Wu EY, et al. Recent Advances in Pediatric Vasculitis. Rheum Dis Clin North Am. 2021;47(4):781-796.
Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
Ozen S, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Ann Rheum Dis. 2010;69(5):798-806.
Sag E, Batu ED, Ozen S. Childhood systemic vasculitis. Best Pract Res Clin Rheumatol. 2017;31(4):558-575.
Ercan Emreol H, et al. New avenues in childhood vasculitis. Pediatr Rheumatol Online J. 2025;23:97.
Cabral DA, et al. Classification, presentation, and initial treatment of pediatric vasculitis. Pediatr Rheumatol. various cohort reports.
Scott C, et al. Medium-vessel and large-vessel vasculitis in children. Curr Opin Rheumatol. 2023;35(5):278-284.
Childhood-Onset ANCA-Associated Vasculitis: From Genetic Studies to Advances in Pathogenesis, Classification and Novel Therapeutic Approaches. Int J Mol Sci. 2024;25(24):13704.
Guidelines for the diagnosis and management of childhood immunoglobulin A vasculitis. World J Pediatr. 2025;21(10):957-972.
American Heart Association guidelines for Kawasaki disease diagnosis and management (updated statements).
SHARE recommendations for childhood vasculitis and IgA vasculitis nephritis.
KDIGO Clinical Practice Guideline updates relevant to IgA vasculitis nephritis.
Vasculitis Foundation and ACR/VF treatment guidance summaries for pediatric practice.
Additional supporting cohort and review literature on epidemiology, outcomes, and emerging therapies cited within the text.